<DOC>
	<DOCNO>NCT00003431</DOCNO>
	<brief_summary>RATIONALE : Flt3L may stimulate person 's immune system help kill tumor cell . PURPOSE : Phase I trial study effectiveness flt3L give patient undergo surgery remove metastases colorectal cancer .</brief_summary>
	<brief_title>Flt3L Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety feasibility administer flt3 ligand patient hepatic metastasis colorectal cancer prior surgical resection . OUTLINE : Patients receive flt3 ligand subcutaneously 14 day follow 14 day rest . This course therapy may repeat total 3 course . Leukapheresis perform day 15 last course Flt3 ligand . Patients undergo restaging metastasis resection . Patients follow every 3 month first year , every 6 month second year , yearly thereafter . PROJECTED ACCRUAL : This study accrue 12 patient 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Flt3 ligand protein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colon cancer express carcinoembryonic antigen ( CEA ) At least 50 % tumor cell must express CEA least moderate intensity Resectable hepatic metastasis site metastatic colon cancer resectable ( e.g. , lung metastasis ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1000/mm3 Absolute lymphocyte count least 1000/mm3 Hemoglobin least 9 mg/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL No hepatic disease Renal : Creatinine le 2.5 mg/dL Cardiovascular : No ongoing cardiac disease No New York Heart Association class III IV heart disease Pulmonary : No ongoing pulmonary disease : Asthma Chronic obstructive pulmonary disease ( COPD ) Active radiation druginduced pneumonitis Other : Not pregnant nursing Fertile patient must use effective contraception No history autoimmune disease limit : Inflammatory bowel disease Systemic lupus erythematosus Ankylosing spondylitis Scleroderma Type I diabetes Multiple sclerosis No serious ongoing chronic acute illness No medical psychological impediment study compliance No concurrent prior second malignancy except : Nonmelanoma skin cancer Controlled superficial bladder cancer within last 5 year No active chronic infection include : Urinary tract infection HIV Viral hepatitis PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroids No concurrent hormone therapy Radiotherapy : No concurrent radiation therapy Surgery : No specify Other : No immunosuppressive : Azathioprine Cyclosporine A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>liver metastasis</keyword>
</DOC>